Individual Investors

Subscribe to email updates

Subscribe now

Financial Professionals

Subscribe to email updates, or password protected financial professional-only content
email address/username
password

PPH VanEck Vectors Pharmaceutical ETF

  • Fund Description

    VanEck Vectors Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.

  •  
      

    • Fund Ticker

      PPH
    • Exchange

      NASDAQ
    • Commencement

      12/20/2011
    • ETF Structure

      Physical
    • Administrator

      Van Eck Associates
    • Custodian

      Bank of New York Mellon
    • Index Ticker

      MVPPHTR
    • Index Rebalancing

      Quarterly
  •  
    as of 07/25/16

    • 30-Day SEC Yield1

      1.69%
    • Total Net Assets

      $271.3M
    • Number of Holdings

      26
    • Options

      Available
    • Gross Expense Ratio2

      0.41%
    • Net Expense Ratio/TER2

      0.36%
    • Distribution Frequency

      Quarterly
    • Next Distribution Date

      09/30/2016
  • Key Points

    Highly Liquid Companies 
    Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume
    Industry Leaders
    Index methodology favors the largest companies in the industry
    Global Scope 
    Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation
     
  • Trading Information

    • Fund Ticker

      PPH
    • Index Total Return Ticker

      MVPPHTR
    • NAV

      PPHNV
    • Intraday NAV (IIV)4

      PPHIV
    • Shares Outstanding

      4,438,138
    • Estimated Cash

      PPHEU
    • Total Cash

      PPHTC
    • CUSIP

      92189F692
    • ISIN

      US92189F6925
    Source: Bloomberg
  • Fees and Expenses2

    • Management Fee

      0.35%
    • Other Expenses

      0.06%
    • Gross Expense Ratio

      0.41%
    • Fee Waivers and
      Expense Reimbursement

      -0.05%
    • Net Expense Ratio/TER2

      0.36%
    2 Expenses for PPH are capped contractually at 0.35% until at least February 1, 2017. Cap excludes certain expenses, such as interest.
  • Prices as of 07/25/16

    NAV/
    Last Price
    Volume
    30-Day Avg./
    Last Trading Day
    Daily Change
    NAV/
    Last Price
    YTD Change
    NAV/
    Last Price
    Premium/
    Discount
    Prem/Discount
    Distribution Charts
    NAV &
    Prem/Discount
    History
    NAV
    Chart
    PPH $61.13
    $61.11
    37,899
    9,398
    -$0.01 / -0.02%
    $-0.07 / -0.11%
    -4.6%
    -4.7%
    $-0.02
    -0.03%
  • View All Indices » View All ETFs » Performance History: Average Annual Total Returns* (%)

    1 MO* 3 MO* YTD* 1 YR 3 YR 5 YR 10 YR LIFE
    12/20/11
    PPH (NAV) -0.24 3.12 -8.83 -15.26 11.08 -- -- 13.97
    PPH (Share Price) -0.42 3.03 -9.01 -15.30 11.06 -- -- 14.19
    MVPPHTR (Index) -0.20 3.19 -9.05 -15.20 11.07 -- -- 13.91
    Performance Differential (NAV - Index) -0.04 -0.07 0.22 -0.06 0.01 -- -- 0.06
    Quarter End as of 06/30/16
    1 MO* 3 MO* YTD* 1 YR 3 YR 5 YR 10 YR LIFE
    12/20/11
    PPH (NAV) -0.24 3.12 -8.83 -15.26 11.08 -- -- 13.97
    PPH (Share Price) -0.42 3.03 -9.01 -15.30 11.06 -- -- 14.19
    MVPPHTR (Index) -0.20 3.19 -9.05 -15.20 11.07 -- -- 13.91
    Performance Differential (NAV - Index) -0.04 -0.07 0.22 -0.06 0.01 -- -- 0.06
  • Daily Holdings »Top 10 Holdings (%)  as of 06/30/16

    Total Holdings: 26
    Holding Name
    Ticker
    SharesMarket Value
    (US$)
    % of Net
    Assets
    Johnson & Johnson
    JNJ US
    114,042
    13,833,2955.31
    Glaxosmithkline Plc
    GSK US
    310,654
    13,463,7445.17
    Novartis Ag
    NVS US
    162,256
    13,387,7435.14
    Sanofi
    SNY US
    318,983
    13,349,4395.13
    Abbvie Inc
    ABBV US
    213,931
    13,244,4685.09
    Bristol-Myers Squibb Co
    BMY US
    179,894
    13,231,2045.08
    Merck & Co Inc
    MRK US
    229,190
    13,203,6365.07
    Pfizer Inc
    PFE US
    374,636
    13,190,9345.07
    Eli Lilly & Co
    LLY US
    158,661
    12,494,5544.80
    Novo Nordisk A/S
    NVO US
    230,954
    12,420,7064.77
    Top 10 Total (%)50.63
    These are not recommendations to buy or to sell any security. Securities and holdings may vary.
  • Country Weightings (%) as of 06/30/16

    • Country

      % of Net Assets
    • UNITED STATES

      70.72
    • UNITED KINGDOM

      9.82
    • SWITZERLAND

      5.14
    • FRANCE

      5.13
    • DENMARK

      4.77
    • ISRAEL

      4.25
    • Other/Cash

      0.17
  • Sector Weightings (%) as of 06/30/16

    • Sector

      % of Net Assets
    • Health Care

      99.8
    • Other/Cash

      0.2